Q32 Bio Inc. Common Stock (QTTB) is a publicly traded Healthcare sector company. As of May 21, 2026, QTTB trades at $5.61 with a market cap of $97.50M and a P/E ratio of 2.04. QTTB moved -6.43% today. Year to date, QTTB is +68.25%; over the trailing twelve months it is +220.34%. Its 52-week range spans $1.35 to $53.17. Analyst consensus is buy with an average price target of $14.33. Rallies surfaces QTTB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Q32 Bio Raises $10.5M, Holds $50.8M Cash and Doses First Open-Label Extension Patient: Q32 Bio is on-track to report 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial by mid-2026 and has dosed the first patient in the open-label extension. It raised $10.5 million via a registered direct offering and held $50.8 million in cash at March 31, 2026, funding into 1H 2028.
| Metric | Value |
|---|---|
| Price | $5.61 |
| Market Cap | $97.50M |
| P/E Ratio | 2.04 |
| EPS | $2.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $53.17 |
| 52-Week Low | $1.35 |
| Volume | 123 |
| Avg Volume | 0 |
| Revenue (TTM) | $53.92M |
| Net Income | $33.24M |
| Gross Margin | 0.00% |
3 analysts cover QTTB: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.33.